Welcome to AusBio

Aus Bio Ltd. is a public but unlisted, Melbourne based biotechnology research and development company (R&D). Principal objectives are:

1. Development of an innovative research program to create new therapeutic products for specific disease states eg influenza.
2. Create significant scientific and commercial alliances.
3. Increase shareholder value.

2020 AGM Chairman's Address

Wednesday 18 November 2020
11:00 AM AEDT

2020 AGM Virtual Meeting - Slides

AGM Presentation.

2020 AGM Virtual Meeting - Voting

Result of Annual General Meeting (ASX Report).

2020 Annual Report and Financial Statements

Full signed financial statements (financial year 2020).

2020 Operational Review

On behalf of your board we are pleased to present the 2020 Review of Operations, Scientific Advisory Panel and Corporate Governance Statements.

AusVir Press Release

Melbourne, Australia; 5 March 2020.
A newly formed biopharmaceutical company AusVir Therapeutics Pty Ltd, focused on the development and commercialization of novel medicines targeting viral infection, today announced that it has raised AUD$23 million in a Series A financing led by Morningside Venture Investments.

Aus Bio in Bloomberg

“New Drugs are Coming to Fight Nasty Flu Seasons”

Influenza

Aus Bio’s MD2009 project has resulted in the pre-clinical development of a number of antiviral drug candidates which have a different mode of action to the currently used neuraminidase inhibitors.

Respiratory

Aus Bio’s Respiratory Project – MD990 – has resulted from the identification of several specific carbohydrates, which have been shown to influence and enhance recovery of injured human respiratory cells.